THÔNG TIN TÀI LIỆU
Thông tin cơ bản
| Định dạng | |
|---|---|
| Số trang | 175 |
| Dung lượng | 8,33 MB |
Nội dung
Ngày đăng: 26/07/2021, 08:45
Nguồn tham khảo
| Tài liệu tham khảo | Loại | Chi tiết |
|---|---|---|
| 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86 | Khác | |
| 2. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non- small-cell lung cancer. Nat Rev Cancer. 2010;10(11):760-74 | Khác | |
| 3. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med.2013;19(5):557-66 | Khác | |
| 4. Krishnan A, Nair SA, Pillai MR. Biology of PPAR gamma in cancer: a critical review on existing lacunae. Curr Mol Med. 2007;7(6):532-40 | Khác | |
| 5. A IJ, Jeannin E, Wahli W, Desvergne B. Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J Biol Chem. 1997;272(32):20108-17 | Khác | |
| 6. Helsen C, Claessens F. Looking at nuclear receptors from a new angle. Mol Cell Endocrinol. 2014;382(1):97-106 | Khác | |
| 7. Schupp M, Lazar MA. Endogenous ligands for nuclear receptors: digging deeper. J Biol Chem. 2010;285(52):40409-15 | Khác | |
| 8. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy- delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83(5):803-12 | Khác | |
| 9. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med. 1999;16(3):179-92 | Khác | |
| 10. Ikeda T. Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case. Drug Metab Pharmacokinet. 2011;26(1):60-70 | Khác | |
| 11. Rawson NS. Review of the quality of observational studies of the association between rosiglitazone and acute myocardial infarction. J Popul Ther Clin Pharmacol.2014;21(2):e214-32 | Khác | |
| 12. Ryder RE. Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit. Diabet Med. 2015;32(3):305-13 | Khác | |
| 13. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994;79(7):1147-56 | Khác | |
| 14. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology. 2003;144(6):2201-7 | Khác | |
| 16. Majdalawieh A, Ro HS. PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1.Nucl Recept Signal. 2010;8:e004 | Khác | |
| 17. Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta. 1998;1378(1):F21-59 | Khác | |
| 18. Keshamouni VG, Han S, Roman J. Peroxisome proliferator-activated receptors in lung cancer. PPAR Res. 2007;2007:90289 | Khác | |
| 19. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer.Cancer Res. 2000;60(4):1129-38 | Khác | |
| 20. Bren-Mattison Y, Van Putten V, Chan D, Winn R, Geraci MW, Nemenoff RA. Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small- cell lung cancer cells (NSCLC). Oncogene. 2005;24(8):1412-22 | Khác |
TÀI LIỆU CÙNG NGƯỜI DÙNG
TÀI LIỆU LIÊN QUAN